Spanish Private Hospital to Sell EarlyCDT®-Lung

RNS Number : 8075T

Oncimmune Holdings PLC

25 March 2019

 

25 March 2019

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Largest Private Hospital Network in Spain to Sell EarlyCDT^®-Lung
as a Screening Test

Additional EarlyCDT-Lung Distribution Agreement in Cyprus

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces that its Spanish distributor, Sabartech, has signed an agreement to sell EarlyCDT-Lung as a screening test for the early detection of lung cancer through the hospitals and clinics of the Quirónsalud group ("Quirónsalud").

Quirónsalud operates the largest private hospital network in Spain with 46 hospitals, 56 outpatient centres and some 300 occupational risk centres. It is headquartered in Madrid and active in every major metropolitan region of Spain. Quirónsalud handles over 330,000 in-patient and 9 million out-patient cases per year. Quirónsalud is owned by Fresenius Helios, Europe's largest private hospital operator.

Every year in Spain approximately 27,000 new cases are diagnosed and approximately 23,000 deaths occur from lung cancer. Lung cancer is the largest cause of cancer-related deaths in Spain[1].

Oncimmune has also signed a distribution agreement with Varnavas Hadjipanayis Ltd for EarlyCDT-Lung for Cyprus. This brings the total aggregate number of distribution agreements to 19.

 

Dr Adam M Hill, CEO of Oncimmune said: "Today's announcement marks another positive step in realising the commercial value of our first marketed test, EarlyCDT-Lung, based on the recognition of its ability to detect cancer four years or more earlier than standard diagnosis.

"With more than £33 million in minimum sales commitments over the next five years, we look forward to providing further updates on sales growth. Today's announcement also validates our strategy of accelerating value creation through partnering."

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Mike Seabrook

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time 

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally. 

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT-Lung and EarlyCDT-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK has a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

For more information, visit www.oncimmune.com

 

---

[1] GLOBOCAN 2018 (WHO)

 

END

 

 

MSCDMGZFMDMGLZZ